- Status:
- In progress
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 858
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- Peninsula Technology Assessment Group (PenTAG), University of Exeter
Stakeholders
- Companies sponsors
- Novartis (everolimus)
- Pfizer (sunitinib)
- Others
- Department of Health
- NHS England
- Welsh Government
- Patient carer groups
- The NET Patient Foundation
- Professional groups
- British Institute of Radiology
- British Nuclear Medicine Society
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Comparator companies
- Accord Healthcare (CAU not returned, not participating)
- Allergan UK (CAU not returned, not participating)
- Hospira UK (CAU not returned, not participating)
- Janssen (CAU not returned, not participating)
- medac GmBH (CAU not returned, not participating)
- Merck Sharp and Dohme (CAU not returned, not participating)
- Novartis (octreotide long acting release)
- Pfizer (doxorubicin)
- Roche Products (CAU not returned, not participating)
- Sun Pharmaceuticals UK (CAU not returned, not participating)
- Teva Pharma (CAU not returned, not participating)
- General commentators
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Welsh Health Specialised Services Committee
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 28 June 2017 | Expected publication |
| 14 June 2017 | The scope for this technology appraisal included lutetium-177 dotatate (177Lu-dotatate). NICE cannot release any recommendations on 177Lu-dotatate until it has a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use. A separate document with the committee’s recommendations will be released when this opinion is received. Information about this separate document can be found on the NICE website. |
| 12 May 2017 - 26 May 2017 | Final appraisal determination |
| 28 February 2017 | Committee meeting: 1 |
| 25 May 2016 | Invitation to participate |
| 22 February 2016 | Draft scope documents |
| 04 November 2015 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual